期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 131, 期 2, 页码 391-400出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2010.280
关键词
-
类别
资金
- National Institutes of Health (NIH), National Center for Research Resources (NCRR) [UL1 RR024143]
- Milstein Program in Medical Research
- NIH [UL1 RR024143]
- Doris Duke Charitable Foundation
- [1 K23 AR052404-01A1]
Psoriasis is a complex inflammatory disease that usually heals without visible scarring. Histological evaluation often suggests complete resolution, but reversal of genomic disease-associated alterations has not yet been defined. Gene expression profiling was used to determine the extent to which the psoriasis genes were reversed after 3 months of etanercept treatment in patients who responded to treatment. We reviewed the histology, leukocyte counts, and PCR data for inflammatory genes, to compare recovery of these parameters and the genomic studies. Many cellular markers do return close to nonlesional levels, although five inflammatory genes did not improve by >75% (IL-12p35, MX1, IL-22, IL-17, and IFN gamma). Psoriasis-related genes with <75% improvement were defined as comprising a residual disease genomic profile,'' composed of 248 probe sets. Genes of interest in psoriasis tissue that did not return to baseline included LYVE-1, WNT5A, RAB31, and AQP9. It appears that even when the epidermal reaction in psoriasis is fully resolved, inflammation, as defined by expression of key cytokines and chemokines, is not completely resolved in treated lesions. We also found that structural cells of the skin continued to express molecular alterations, and that some subtle features of skin structure, for example, lymphatics, were not fully normalized with treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据